Insider

Regeneron co-chief scientific officer exercises options and sells shares

Regeneron Pharmaceuticals co-chief scientific officer Andrew J. Murphy exercised 17,000 stock options on October 13 and sold 4,147 shares on October 14. The trades occurred under a pre-approved trading plan, reflecting a standard schedule to cover tax obligations and exercise option rights.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
Two scientists working on computers in a laboratory
Photo by Chidera Faustina Okeke on Unsplash
4,147
Shares sold
$772.6973
Average sale price
17,000
Options exercised

Key points

  • On October 13, Andrew J. Murphy exercised 17,000 company stock options.
  • Stock sales under a pre-approved Rule 10b5-1 plan should not be interpreted as an assessment of the company’s prospects or a loss of executive confidence.

Insider transaction details

On October 13, Andrew J. Murphy exercised 17,000 company stock options. The company withheld 12,853 shares to cover taxes and the cost of exercising the options, a standard procedure for such transactions.

The following day, October 14, Andrew J. Murphy sold 4,147 shares on the open market at a weighted average price of $772.6973. The sale occurred under a Rule 10b5-1 plan, a preset selling schedule executives set up in advance to avoid suspicions of using non-public information. This plan was adopted on May 7, 2026.

What these sales mean

Stock sales under a pre-approved Rule 10b5-1 plan should not be interpreted as an assessment of the company’s prospects or a loss of executive confidence. Such transactions are often executed automatically according to previously scheduled dates or price levels, rather than due to sudden business changes.

Original sources

  1. 144 filing, October 14, 2026October 14, 2026SHA-256 of our archived copy d9ef9f280ec2…
  2. 4 filing, October 15, 2026October 15, 2026SHA-256 of our archived copy 336d78033ec5…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards